高级检索
当前位置: 首页 > 详情页

Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [3]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Palliative Care Center and Day Care, Peking University Cancer Hospital and Institute, Beijing, China
出处:
ISSN:

关键词: MiR-552 Colorectal cancer Prognosis

摘要:
OBJECTIVE: MiR-552 has recently been identified to be involved in tumorigenesis of colorectal cancer (CRC). The aim of this study was to determine if miR-552 could serve as a prognosis indicator for patients with CRC. PATIENTS AND METHODS: MiR-552 expression levels were detected in 183 pairs of primary CRC and their matched non-tumor tissues by qPCR. The association between miR-552 expression and clinicopathological parameters was analyzed. The survival curves were calculated by the Kaplan-Meier method. Univariate and multivariate analyses were performed to explore the prognostic significance of miR-552 expression. RESULTS: We found that miR-552 expression was upregulated in CRC tumor tissues compared to their adjacent normal tissues (p < 0.01). Increased miR-552 expression was significantly associated with histological grade (p = 0.000), lymph nodes metastasis (p = 0.022) and TNM stage (p = 0.002). In addition, the patients with high miR-552 expression had a significantly worse 5-year overall survival rate than those with low miR-552 expression (p = 0.0036). Furthermore, according to univariate and multivariate analysis, elevated miR-552 was confirmed to be an independent prognostic factor for worse survival. CONCLUSIONS: T he current results demonstrated that high miR-552 expression was associated with poor outcomes in patients with CRC. MiR-552 may be a potential prognostic biomarker and therapeutic target in CRC patients.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2025]版:
JCR分区:
出版当年[2018]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2024]版:

影响因子: 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
通讯作者:
通讯机构: [2]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [3]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Palliative Care Center and Day Care, Peking University Cancer Hospital and Institute, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号